Albert A. Antolin
Albert A. Antolin
Sir Henry Wellcome PostDoctoral Fellow, The Institute of Cancer Research, UK
Verified email at icr.ac.uk - Homepage
Title
Cited by
Cited by
Year
In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals targeting opportunities
C Rubio-Perez, D Tamborero, MP Schroeder, AA Antolín, J Deu-Pons, ...
Cancer cell 27 (3), 382-396, 2015
2842015
Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen
MP Menden, D Wang, MJ Mason, B Szalai, KC Bulusu, Y Guan, T Yu, ...
Nature communications 10 (1), 1-17, 2019
1282019
canSAR: an updated cancer research and drug discovery knowledgebase
JE Tym, C Mitsopoulos, EA Coker, P Razaz, AC Schierz, AA Antolin, ...
Nucleic acids research 44 (D1), D938-D943, 2016
852016
Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology
AA Antolin, X Jalencas, J Yelamos, J Mestres
ACS chemical biology 7 (12), 1962-1967, 2012
722012
Polypharmacology in precision oncology: current applications and future prospects
A A Antolin, P Workman, J Mestres, B Al-Lazikani
Current pharmaceutical design 22 (46), 6935-6945, 2016
552016
Objective, quantitative, data-driven assessment of chemical probes
AA Antolin, JE Tym, A Komianou, I Collins, P Workman, B Al-Lazikani
Cell chemical biology 25 (2), 194-205. e5, 2018
442018
Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors
AA Antolín, J Mestres
Oncotarget 5 (10), 3023, 2014
432014
Distant polypharmacology among MLP chemical probes
AA Antolin, J Mestres
ACS chemical biology 10 (2), 395-400, 2015
282015
The kinase polypharmacology landscape of clinical PARP inhibitors
AA Antolin, M Ameratunga, U Banerji, PA Clarke, P Workman, ...
Scientific reports 10 (1), 1-14, 2020
262020
canSAR: update to the cancer translational research and drug discovery knowledgebase
EA Coker, C Mitsopoulos, JE Tym, A Komianou, C Kannas, P Di Micco, ...
Nucleic acids research 47 (D1), D917-D922, 2019
262019
Transforming cancer drug discovery with Big Data and AI
P Workman, AA Antolin, B Al-Lazikani
Expert opinion on drug discovery 14 (11), 1089-1095, 2019
162019
Exploring the effect of PARP-1 flexibility in docking studies
AA Antolin, A Carotti, R Nuti, A Hakkaya, E Camaioni, J Mestres, ...
Journal of Molecular Graphics and Modelling 45, 192-201, 2013
152013
canSAR: update to the cancer translational research and drug discovery knowledgebase
C Mitsopoulos, P Di Micco, EV Fernandez, D Dolciami, E Holt, IL Mica, ...
Nucleic Acids Research 49 (D1), D1074-D1082, 2021
62021
Public resources for chemical probes: the journey so far and the road ahead
AA Antolin, P Workman, B Al-Lazikani
Future medicinal chemistry 13 (08), 731-747, 2021
52021
Coronavirus canSAR–a data-driven, AI-enabled, drug discovery resource for the research community
C Mitsopoulos, AA Antolin, EV Fernandez, P Di Micco, IL Micca, JE Tym, ...
22020
The off-target kinase landscape of clinical PARP inhibitors
AA Antolin, M Ameratunga, U Banerji, PA Clarke, P Workman, ...
bioRxiv, 520023, 2019
22019
Dual inhibitors of PARPs and ROCKs
AA Antolín, J Mestres
ACS omega 3 (10), 12707-12712, 2018
22018
Abstract B096: canSAR, a cancer research and drug discovery knowledgebase
EA Coker, P Di Micco, JE Tym, C Mitsopoulos, A Komianou, AA Antolin, ...
Molecular Cancer Therapeutics 17 (1 Supplement), B096-B096, 2018
22018
In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals novel targeting opportunities
C Rubio-Perez, D Tamborero, MP Schroeder, AA Antolin, J Deu-Pons, ...
Cancer Research 75 (15 Supplement), 2983-2983, 2015
22015
Knowledge base for nuclear receptor drug discovery
AA Antolín, J Mestres
Therapeutic Targets: Modulation, Inhibition, and Activation, 309-326, 2012
22012
The system can't perform the operation now. Try again later.
Articles 1–20